Many patients with metastatic prostate cancer currently miss out on optimal treatments due to fragmented care, geographic hurdles, and inconsistent clinical practices. By addressing these disparities, the NCCN aims to replace uneven standards with scalable, evidence-based strategies that improve long-term outcomes. NCCN CEO Crystal S. Denlinger emphasized that these projects prioritize sustainability, ensuring that findings can be applied well beyond individual institutions.
NCCN Backs Research to Close Metastatic Prostate Cancer Treatment Gaps
The National Comprehensive Cancer Network has awarded funding for four new quality improvement projects aimed at overcoming systemic barriers in metastatic prostate cancer care. Supported by Pfizer Global Medical Grants, these initiatives seek to standardize diagnostic testing and expand access to life-prolonging therapies across diverse U.S. patient populations.
The selected research projects include Dr. Changchuan Jiang’s work at UT Southwestern on biomarker action loops, and Dr. Paul Leger’s multilevel intervention program at Georgetown University. Meanwhile, Dr. Michael Liu at Northwestern focuses on reducing polypharmacy burdens for better treatment tolerability, while Dr. Kosj Yamoah at Moffitt Cancer Center is developing a closed-loop pathway for molecular testing during bone radiotherapy. A committee of peer experts selected these recipients, who have two years to complete their initiatives.
Comments (0)
No comments yet. Be the first!